Ivan Tjong-A-Hung
HEOR & RWE 中国担当ディレクター
Expertise:
Dr. Ivan Tjong-A-Hung is a business leader for Health Economic and Outcomes Research & Real-World Evidence (HEOR and RWE) with over 30 years of experience in the Healthcare Industry. At EVERSANA China, he leads the business development activities and is building an experienced dedicated team for HEOR & RWE services.
Prior to joining EVERSANA, Ivan worked at Pfizer, Sanofi and Athena Healthcare Consultancy with placements in the Netherlands, France and China. He has extensive experience in Marketing, Medical Affairs, R&D, Consulting and in the design & application of HEOR & RWE to Brand communication, medico-marketing and sales.
Ivan’s academic training includes a MD from the University of Utrecht in the Netherlands and an MBA with specialization in finance from the University of Manchester in the UK. He has also completed a Postgraduate course in Pharmaceutical Medicine (University of Wales, the UK).
Articles by Ivan Tjong-A-Hung
Matching-Adjusted Indirect Comparison (MAIC): An Established Methodology for Comparing Treatment Efficacies Across Trials
In the realm of comparative effectiveness research (CER), decision-makers often face challenges when attempting to compare treatment efficacies due to limited availability of comparative data, especially for new therapies. This white paper introduces the Matching-Adjusted Indirect Comparison (MAIC) methodology as a powerful technique for addressing these evidence gaps. MAIC combines individual patient data (IPD) from one treatment with published aggregate data from another, allowing for greater adjustment of observed cross-trial differences. By reweighting patients and performing matching based on odds, MAIC enables the comparison of treatment outcomes between balanced populations. This approach has been successfully applied in various therapeutic areas, providing valuable insights before the publication of randomized comparative studies. […]